# The dose-dependent efficacy of esketamine in spinal surgery with intraoperative neuroelectrophysiological monitoring: a randomized controlled trial

**Authors:** Chunyan Lin, Jianlin Wang, Long Zhang, Liyong Yuan, Guanyi Liu, Miao Zhu, Liangguang Zhang

PMC · DOI: 10.3389/fmed.2025.1579908 · 2025-06-18

## TL;DR

This study tested different doses of esketamine during spinal surgery and found that 0.3 mg/kg/h is safe and effective for better recovery and fewer complications.

## Contribution

The study introduces the dose-dependent efficacy of esketamine in spinal surgery under IONM, with a focus on optimal dosing for safety and recovery.

## Key findings

- Group B (0.3 mg/kg/h esketamine) used less anesthetic and had fewer complications.
- Group C (0.5 mg/kg/h esketamine) had lower pain scores but longer awakening times.
- All esketamine groups showed better recovery and cognitive scores than the control group.

## Abstract

This study aims to validate the efficacy and safety of combining different doses of esketamine with propofol, remifentanil, and dexmedetomidine in spinal surgery under intra-operative neuroelectrophysiological monitoring (IONM).

All enrolled patients underwent a total intravenous anesthesia (TIVA) maintenance regimen, which included propofol, remifentanil, and dexmedetomidine. The patients were randomly assigned to four groups based on the use and dosage of esketamine: Group Control (TIVA + NS), Group A (TIVA + Esketamine 0.1 mg/kg/h), Group B (TIVA + Esketamine 0.3 mg/kg/h), and Group C (TIVA + Esketamine 0.5 mg/kg/h). The study measured vital signs, consumption of anesthetics, operation time, blood loss, awakening time in the postanesthesia care unit (PACU), visual analog scale (VAS) pain score, quality of recovery (QoR) -15 score, and dosage of supplementary analgesics. Additionally, adverse postoperative reactions were recorded.

Group B had lower dosages of propofol (P = 0.021), remifentanil (P = 0.001), and dexmedetomidine (P < 0.001) than the Control Group, while Group C had lower dosages of remifentanil and dexmedetomidine (P < 0.001) than the Control Group. The postoperative mean arterial pressure (MAP) was lower in Group B than in the Control Group (P = 0.028). Patients in Group C experienced a prolonged awakening time (P < 0.001) but had lower VAS pain scores at PACU than those in the Control group (P = 0.044). Both QoR-15 scores and MoCA scores were significantly higher for patients in Groups A, B, and C compared to those of the Control group (QoR-15: P = 0.001, < 0.001, < 0.001; MoCA: P = 0.004, < 0.001, < 0.001). Group B had few postoperative complications.

The dose of 0.3 mg/kg/h esketamine is safe and effective for spinal surgery with IONM, improving control of postoperative complications.

## Linked entities

- **Chemicals:** esketamine (PubChem CID 182137), propofol (PubChem CID 4943), remifentanil (PubChem CID 60815), dexmedetomidine (PubChem CID 5311068)

## Full-text entities

- **Diseases:** pain (MESH:D010146), blood loss (MESH:D016063)
- **Chemicals:** Esketamine (MESH:C000629870), remifentanil (MESH:D000077208), propofol (MESH:D015742), dexmedetomidine (MESH:D020927)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12213778/full.md

---
Source: https://tomesphere.com/paper/PMC12213778